No deaths associated with patient refusal of transport after naloxone-reversed opioid overdose - PubMed (original) (raw)
No deaths associated with patient refusal of transport after naloxone-reversed opioid overdose
David A Wampler et al. Prehosp Emerg Care. 2011 Jul-Sep.
Abstract
Introduction: Naloxone is widely used in the treatment and reversal of opioid overdose. Most emergency medical services (EMS) systems administer naloxone by standing order, and titrate only to reverse respiratory depression without fully reversing sedation. Some EMS systems routinely administer sufficient naloxone to fully reverse the effects of opioid overdose. Frequently patients refuse further medical evaluation or intervention, including transport.
Objectives: The purpose of this study was to evaluate the safety of this practice and determine whether increased mortality is associated with full reversal of opioids. As a component of a comprehensive quality assurance initiative, we assessed mortality during the 48 hours after patients received naloxone to reverse opioid overdose followed by patient-initiated refusal of transportation.
Methods: The setting was a large urban fire-based EMS system. Investigators provided the Bexar County Medical Examiner's Office (MEO) with a list of patients who were treated by the San Antonio Fire Department with naloxone, and not transported. Inclusion criteria were administration of naloxone and patient-initiated refusal. Patient dispositions also included aid only, referral to the MEO, or referral to law enforcement. The list was then compared with the MEO database. A chart review was completed on all patients treated and subsequently presented to the MEO within two days. A secondary time period of 30 days was also assessed.
Results: The list identified 592 patients treated with naloxone and not transported to the emergency department. Five-hundred fifty-two patients received naloxone and refused transport or were not transported. The remaining 40 patients all presented to EMS in cardiac arrest, naloxone was administered during the course of resuscitation, and subsequent efforts were terminated in the field. None of the patients receiving naloxone with a subsequent patient-initiated refusal were examined at the MEO within the two-day end point. The 30-day assessment revealed that nine individuals were treated with naloxone and subsequently died, but the shortest time interval between date of service and date of death was four days.
Conclusion: The primary outcome was that no patients who were treated with naloxone for opioid overdose and then refused care were examined by the MEO within a 48-hour time frame.
Similar articles
- Recurrent opioid toxicity after pre-hospital care of presumed heroin overdose patients.
Boyd JJ, Kuisma MJ, Alaspää AO, Vuori E, Repo JV, Randell TT. Boyd JJ, et al. Acta Anaesthesiol Scand. 2006 Nov;50(10):1266-70. doi: 10.1111/j.1399-6576.2006.01172.x. Acta Anaesthesiol Scand. 2006. PMID: 17067327 - Can nebulized naloxone be used safely and effectively by emergency medical services for suspected opioid overdose?
Weber JM, Tataris KL, Hoffman JD, Aks SE, Mycyk MB. Weber JM, et al. Prehosp Emerg Care. 2012 Apr-Jun;16(2):289-92. doi: 10.3109/10903127.2011.640763. Epub 2011 Dec 22. Prehosp Emerg Care. 2012. PMID: 22191727 - Randomized controlled trial comparing the effectiveness and safety of intranasal and intramuscular naloxone for the treatment of suspected heroin overdose.
Kerr D, Kelly AM, Dietze P, Jolley D, Barger B. Kerr D, et al. Addiction. 2009 Dec;104(12):2067-74. doi: 10.1111/j.1360-0443.2009.02724.x. Addiction. 2009. PMID: 19922572 Clinical Trial. - Do heroin overdose patients require observation after receiving naloxone?
Willman MW, Liss DB, Schwarz ES, Mullins ME. Willman MW, et al. Clin Toxicol (Phila). 2017 Feb;55(2):81-87. doi: 10.1080/15563650.2016.1253846. Epub 2016 Nov 16. Clin Toxicol (Phila). 2017. PMID: 27849133 Review. - Intranasal naloxone for the treatment of suspected heroin overdose.
Kerr D, Dietze P, Kelly AM. Kerr D, et al. Addiction. 2008 Mar;103(3):379-86. doi: 10.1111/j.1360-0443.2007.02097.x. Addiction. 2008. PMID: 18269360 Review.
Cited by
- Assessment of the safety and ease of use of the naloxone auto-injector for the reversal of opioid overdose.
Merlin MA, Ariyaprakai N, Arshad FH. Merlin MA, et al. Open Access Emerg Med. 2015 Jun 8;7:21-4. doi: 10.2147/OAEM.S82133. eCollection 2015. Open Access Emerg Med. 2015. PMID: 27147886 Free PMC article. Review. - Clinical Pharmacokinetics and Pharmacodynamics of Naloxone.
Saari TI, Strang J, Dale O. Saari TI, et al. Clin Pharmacokinet. 2024 Apr;63(4):397-422. doi: 10.1007/s40262-024-01355-6. Epub 2024 Mar 14. Clin Pharmacokinet. 2024. PMID: 38485851 Free PMC article. Review. - Variations in the California Emergency Medical Services Response to Opioid Use Disorder.
Glober NK, Hern G, McBride O, Mercer MP. Glober NK, et al. West J Emerg Med. 2020 Apr 16;21(3):671-676. doi: 10.5811/westjem.2019.12.45189. West J Emerg Med. 2020. PMID: 32421518 Free PMC article. - Expanding access to naloxone in the United States.
Doyon S, Aks SE, Schaeffer S. Doyon S, et al. J Med Toxicol. 2014 Dec;10(4):431-4. doi: 10.1007/s13181-014-0432-1. J Med Toxicol. 2014. PMID: 25316516 Free PMC article. No abstract available. - At-risk patient documentation and naloxone dispersal for a rural statewide EMS "Naloxone Leave Behind" program.
Naumann J, Benson J, Lamberson M, Hunt S, Moran W, Stevens MW, Wolfson D. Naumann J, et al. J Am Coll Emerg Physicians Open. 2024 May 17;5(3):e13186. doi: 10.1002/emp2.13186. eCollection 2024 Jun. J Am Coll Emerg Physicians Open. 2024. PMID: 38766594 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials